Thomson Reuters Enhances MetaCore Solution with Validated Biomarker Data
(Thomson Reuters ONE) -
Philadelphia, PA, London, UK, May 03, 2011 - Thomson Reuters today announced
that it is to offer access to its validated biomarker content within
MetaCore(TM), the company's pathway analysis and biomarker discovery solution.
The announcement marks a further step forward in providing the life sciences
industry with unparalleled resources for biomarker discovery and development.
The enhanced access will provide users of MetaCore with additional gene and
biomarker data including biomarker name, type and role as well as gene name
within their search results. The additional data is drawn from Thomson Reuters
Integrity(SM), the industry's largest source of validated biomarker data, with
more than 7,000 biomarkers and 200,000 related uses. The development will
provide deeper insight into potential biomarkers identified in MetaCore,
including previous utility, extent of research already performed and level of
confidence in that biomarker.
"Biomarkers are playing an increasingly important role in the development of new
drugs and treatments," said Jon Brett-Harris, executive vice president, Thomson
Reuters. "This latest addition to MetaCore marks the first step towards a
comprehensive solution for biomarker discovery, hypothesis testing and
validation, enabling scientists to go from basic 'omics' data to biomarker
insight in hours."
Inclusion of the biomarkers data in MetaCore will strengthen its appeal among
scientists and researchers working in translational medicine, or involved in the
identification of biomarkers for use in internal decision making for early
research and development projects.
MetaCore is an integrated solution and software suite for pathway analysis of
experimental data and gene lists. The solution enables scientists to discover
and hypothesize on potential new biomarkers, either through pathway exploration
or through the interpretation of experimentally derived 'omics' data.
Thomson Reuters Integrity integrates biology, chemistry and pharmacology data on
more than 340,000 compounds with demonstrated biological activity and almost
160,000 patent family records providing researchers with reliable, detailed
information across multiple disciplines.
The life sciences business of Thomson Reuters works closely with the
pharmaceutical, biotechnology, and academic research communities to deliver
solutions that provide a better understanding of the underlying mechanism of
disease and potential therapies.
For more information about MetaCore, please visit:
http://www.genego.com/metacore.php
Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for
businesses and professionals. We combine industry expertise with innovative
technology to deliver critical information to leading decision makers in the
financial, legal, tax and accounting, healthcare and science and media markets,
powered by the world's most trusted news organization. With headquarters in New
York and major operations in London and Eagan, Minnesota, Thomson Reuters
employs 55,000 people and operates in over 100 countries. For more information,
go towww.thomsonreuters.com.
CONTACT
Paul Sandell
Manager, PR & Communications
IP & Science
+44 (0) 207 433 4704
paul.sandell(at)thomsonreuters.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Thomson Reuters Corporation via Thomson Reuters ONE
[HUG#1508591]
Unternehmensinformation / Kurzprofil:
Datum: 03.05.2011 - 06:02 Uhr
Sprache: Deutsch
News-ID 54136
Anzahl Zeichen: 4214
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 241 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Thomson Reuters Enhances MetaCore Solution with Validated Biomarker Data"
steht unter der journalistisch-redaktionellen Verantwortung von
Thomson Reuters Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
